Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020



Alain Vertès

Alain Vertès

Managing Director, NxR Biotechnologies

Dr Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland, where he advises clients on strategy, business development, in/out-licensing, entrepreneurship and investment. He brings to his role extensive experience in the pharmaceutical and industrial biotechnology sectors, in Europe, North America and Asia and in different functions including research, manufacturing, contract research, and strategic alliances. NxR's track record comprises projects with big pharmas, biotechs, generics companies, financial investors, CROs, academia, and start-ups. Active in alliance management for Mesoblast, prior to NxR Biotechnologies Dr Vertès held positions of increasing responsibility in pharmaceuticals at Lilly and Pfizer, as well as at Roche where he notably led through an external innovation partnering function the global cell therapeutics strategy and implementation team in 2007-2010. In addition, he has worked in petrochemicals at Mitsubishi Chemical Corporation, public research at the Institut Pasteur Paris and RITE/Kyoto, contract research at Battelle Memorial Institute and PPD/BioDuro, and has done consulting for the Australian Strategic Policy Institute. With a focus on innovation commercialization, he has been a key player in the evaluation, selection, deal making, implementation and alliance management of numerous novel products and emerging technologies.

Dr Vertès received his M.Sc. degree from the University of Illinois at Urbana-Champaign, his Ph.D. from the University of Lille Flandres Artois and is a Sloan Fellow from London Business School (MBA/M.Sc.). Dr Vertès is a lead editor of several science and strategy books in the fields of regenerative medicine and sustainable chemistry.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd